D-0790-2020 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0790-2020 was initiated by Lupin Pharmaceuticals Inc. on Jan 10, 2020 and is designated Class III. Reason for recall: CGMP Deviations: Out of specification test result observed during retrospective review of blend uniformity test data. The recall status is terminated (terminated Jun 3, 2021). Affected quantity: 34,080 boxes (3 wallets per carton, 80 cartons per box).

Recall details

Product Type
Drugs
Report Date
Jan 22, 2020
Initiation Date
Jan 10, 2020
Termination Date
Jun 3, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
34,080 boxes (3 wallets per carton, 80 cartons per box)

Product description

Tri-Lo-Marzia (Norgestimate and Ethinyl Estradiol Tablets, USP), 0.180 mg/0.025 mg; 0.215mg/0.025 mg and 0.250 mg/0.025 mg, Pack size - 3 x 28's wallets/carton, Rx Only, Distributed by Lupin Pharmaceuticals, Inc, Baltimore MD 21202, Manufactured by: Lupin Limited, Pithampur, (M.P.)- 454775, India. NDC 68180-837-13 (3x28 carton ) NDC 68180-837-11 (28 tablet wallet)

Reason for recall

CGMP Deviations: Out of specification test result observed during retrospective review of blend uniformity test data.

Distribution pattern

Distributed nationwide in the US

Code information

Lot # L800498, exp. date February 2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0790-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0790-2020. Report a data issue: hello@regdatalab.com.